Advanced

Development of an MRM assay panel with application to biobank samples from patients with Myocardial Infarction.

Rezeli, Melinda LU ; Végvári, Ákos LU ; Donnarumma, Fabrizio LU ; Gidlöf, Olof LU ; Smith, J Gustav; Erlinge, David LU and Marko-Varga, György LU (2013) In Journal of Proteomics2008-01-01+01:00 87(1). p.16-25
Abstract
As part of a Swedish national cardiological research initiative, the development of a quantitative MRM assay is reported for the quantification of eleven putative cardiovascular disease markers. Within the study, patient samples from the LUNDHEARTGENE biobank were processed and nanoLC-MS/MS analysis were performed together with stable isotope dilution strategy for absolute quantification of the target proteins. Excellent linear regressions were achieved for 9 of the 11 peptides with LOQ ranged in the attomolar range. We have utilized the assay for the screening of plasma samples from patients with chest pain, and performed a comparative analysis of patients with ST Segment Elevation Myocardial Infarction and chest pain due to other causes.... (More)
As part of a Swedish national cardiological research initiative, the development of a quantitative MRM assay is reported for the quantification of eleven putative cardiovascular disease markers. Within the study, patient samples from the LUNDHEARTGENE biobank were processed and nanoLC-MS/MS analysis were performed together with stable isotope dilution strategy for absolute quantification of the target proteins. Excellent linear regressions were achieved for 9 of the 11 peptides with LOQ ranged in the attomolar range. We have utilized the assay for the screening of plasma samples from patients with chest pain, and performed a comparative analysis of patients with ST Segment Elevation Myocardial Infarction and chest pain due to other causes. The assay demonstrates high reproducibility and correlate with clinical findings. Strong correlations were found for several of the apolipoproteins and their respective lipid subfractions (LDL, HDL or triglycerides). ApoC1, apoC2 and apoE were elevated in patients with STEMI. BIOLOGICAL SIGNIFICANCE: MRM assay were developed for putative cardiovascular disease markers as target proteins, and applied to biobanking sample material. The comparative analysis of patients with ST Segment Elevation Myocardial Infarction and chest pain due to other causes shows elevated levels of apoC1, apoC2 and apoE in patients with STEMI. These observations raise interesting novel hypotheses about the role of apolipoproteins C1, C2 and E in the pathophysiology of acute myocardial infarction, which merits further studies. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Myocardial infarction, Multiple reaction monitoring, Apolipoproteins
in
Journal of Proteomics2008-01-01+01:00
volume
87
issue
1
pages
16 - 25
publisher
Elsevier
external identifiers
  • pmid:23707545
  • wos:000322058300002
  • scopus:84878898726
ISSN
1874-3919
DOI
10.1016/j.jprot.2013.05.016
language
English
LU publication?
yes
id
22a13d08-5300-4f07-a4ca-78bf4e47e871 (old id 3804137)
date added to LUP
2013-06-11 10:46:59
date last changed
2018-11-21 19:37:58
@article{22a13d08-5300-4f07-a4ca-78bf4e47e871,
  abstract     = {As part of a Swedish national cardiological research initiative, the development of a quantitative MRM assay is reported for the quantification of eleven putative cardiovascular disease markers. Within the study, patient samples from the LUNDHEARTGENE biobank were processed and nanoLC-MS/MS analysis were performed together with stable isotope dilution strategy for absolute quantification of the target proteins. Excellent linear regressions were achieved for 9 of the 11 peptides with LOQ ranged in the attomolar range. We have utilized the assay for the screening of plasma samples from patients with chest pain, and performed a comparative analysis of patients with ST Segment Elevation Myocardial Infarction and chest pain due to other causes. The assay demonstrates high reproducibility and correlate with clinical findings. Strong correlations were found for several of the apolipoproteins and their respective lipid subfractions (LDL, HDL or triglycerides). ApoC1, apoC2 and apoE were elevated in patients with STEMI. BIOLOGICAL SIGNIFICANCE: MRM assay were developed for putative cardiovascular disease markers as target proteins, and applied to biobanking sample material. The comparative analysis of patients with ST Segment Elevation Myocardial Infarction and chest pain due to other causes shows elevated levels of apoC1, apoC2 and apoE in patients with STEMI. These observations raise interesting novel hypotheses about the role of apolipoproteins C1, C2 and E in the pathophysiology of acute myocardial infarction, which merits further studies.},
  author       = {Rezeli, Melinda and Végvári, Ákos and Donnarumma, Fabrizio and Gidlöf, Olof and Smith, J Gustav and Erlinge, David and Marko-Varga, György},
  issn         = {1874-3919},
  keyword      = {Myocardial infarction,Multiple reaction monitoring,Apolipoproteins},
  language     = {eng},
  number       = {1},
  pages        = {16--25},
  publisher    = {Elsevier},
  series       = {Journal of Proteomics2008-01-01+01:00},
  title        = {Development of an MRM assay panel with application to biobank samples from patients with Myocardial Infarction.},
  url          = {http://dx.doi.org/10.1016/j.jprot.2013.05.016},
  volume       = {87},
  year         = {2013},
}